Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial

IMPORTANCE: Acquired resistance to anti-EGFR therapy (epidermal growth factor receptor) is frequently due to RAS and EGFR extracellular domain (ECD) mutations in metastatic colorectal cancer (mCRC). Some anti-EGFR–refractory patients retain tumor EGFR dependency potentially targetable by agents such...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Montagut, Clara, Argilés, Guillem, Ciardiello, Fortunato, Poulsen, Thomas T., Dienstmann, Rodrigo, Kragh, Michael, Kopetz, Scott, Lindsted, Trine, Ding, Cliff, Vidal, Joana, Clausell-Tormos, Jenifer, Siravegna, Giulia, Sánchez-Martín, Francisco J., Koefoed, Klaus, Pedersen, Mikkel W., Grandal, Michael M., Dvorkin, Mikhail, Wyrwicz, Lucjan, Rovira, Ana, Cubillo, Antonio, Salazar, Ramon, Desseigne, Françoise, Nadal, Cristina, Albanell, Joan, Zagonel, Vittorina, Siena, Salvatore, Fumi, Guglielmo, Rospo, Giuseppe, Nadler, Paul, Horak, Ivan D., Bardelli, Alberto, Tabernero, Josep
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2018
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5885274/
https://ncbi.nlm.nih.gov/pubmed/29423521
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.5245
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados